SCHEMBL15545359

SCHEMBL15545359

O=[N+]([O-])c1cc(F)cc(S(F)(F)(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.41
TSHR P16473 2/20 0.39
ALDH1A1 P00352 3/20 0.38
HIF1A Q16665 1/20 0.37
PGR P06401 2/20 0.36
HSPB1 P04792 2/20 0.36
LMNA P02545 2/20 0.35
HTT P42858 2/20 0.35
VCAM1 P19320 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ACHE P22303 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP3A4 P08684 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL816365 0.87 CYP19A1 (0.48) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL9312899 0.87 CYP19A1 (0.54) CYP19A1TSHRALDH1A1HIF1ALMNA
SCHEMBL1172437 0.80 CYP19A1 (0.55) CYP19A1TSHRALDH1A1HIF1APGR
SCHEMBL7203812 0.80 CYP19A1 (0.62) CYP19A1TSHRALDH1A1HIF1APGR
SCHEMBL15544726 0.78 CYP19A1 (0.40) CYP19A1TSHRALDH1A1LMNAHTT
Fluoride SCHEMBL27574861 0.78 CYP19A1 (0.59) CYP19A1TSHRALDH1A1HIF1APGR
SCHEMBL6863360 0.77 ALDH1A1 (0.46) CYP19A1TSHRALDH1A1HIF1ACYP3A4
SCHEMBL28967049 0.76 CYP3A4 (0.47) CYP19A1TSHRALDH1A1LMNAMEN1
SCHEMBL28967021 0.76 XDH (0.39) CYP19A1TSHRALDH1A1LMNAVCAM1
SCHEMBL29985009 0.74 TP53 (0.50) TSHRALDH1A1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104428289-B As the triazole compounds of antivirotic 弗·哈夫曼-拉罗切有限公司 2017-06-23 CN disclosed
EP-2870143-B1 TRIAZOLE COMPOUNDS AS ANTIVIRALS HOFFMANN LA ROCHE (CH) 2017-05-17 EP disclosed
US-20150307461-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2015-10-29 US disclosed
EP-2870143-A1 TRIAZOLE COMPOUNDS AS ANTIVIRALS F. Hoffmann-La Roche AG (CH) 2015-05-13 EP disclosed
US-20140010783-A1 ANTIVIRAL COMPOUNDS HOFFMANN-LA ROCHE INC. 2014-01-09 US disclosed
WO-2014006066-A1 TRIAZOLE COMPOUNDS AS ANTIVIRALS F. HOFFMANN-LA ROCHE AG (CH) 2014-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307461-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS CYP19A1 1667/4885TSHR 4602/4885ALDH1A1 222/4885
US-20140010783-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS CYP19A1 1667/4885TSHR 4602/4885ALDH1A1 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.